Clinical trial

Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)

NCT02393248

Drugs and interventions used in this trial

7 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Pemigatinib Normalized identity: pemigatinibView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Gemcitabine Normalized identity: gemcitabineView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Pembrolizumab Normalized identity: pembrolizumabView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Docetaxel Normalized identity: docetaxelView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Trastuzumab Normalized identity: trastuzumabView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Retifanlimab Normalized identity: retifanlimabView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Cisplatin Normalized identity: cisplatinView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)

Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE1, PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2015-02-27

PhasePHASE1 / PHASE2

Conditions

Lung Cancerverified · MONDO: lung cancer

Solid Tumorunresolved

Gastric Cancerverified · MONDO: gastric cancer

Urothelial Cancerunresolved

Endometrial Cancerverified · MONDO: endometrial cancer

Multiple Myelomaunresolved

Myeloproliferative Neoplasmsunresolved

Breast Cancerverified · MONDO: breast cancer

Cholangiocarcinomaverified · MONDO: cholangiocarcinoma

UCunresolved

MPNverified · MONDO: myeloproliferative neoplasm

Interventions

PemigatinibDRUG · verified · RxNorm: pemigatinib

GemcitabineDRUG · verified · RxNorm: gemcitabine

PembrolizumabDRUG · verified · RxNorm: pembrolizumab

DocetaxelDRUG · verified · RxNorm: docetaxel

TrastuzumabDRUG · verified · RxNorm: trastuzumab

RetifanlimabDRUG · verified · RxNorm: retifanlimab

CisplatinDRUG · verified · RxNorm: cisplatin

Sponsors & collaborators

Incyte Corporationlead sponsor

Mapped research locations

HoustonTexas, United States1 DallasTexas, United States1 St LouisMissouri, United States1 AtlantaGeorgia, United States1 San AntonioTexas, United States1 BirminghamAlabama, United States1 ColumbusOhio, United States1 DurhamNorth Carolina, United States1 Washington D.C.District of Columbia, United States1 Ann ArborMichigan, United States1 New HavenConnecticut, United States1 The BronxNew York, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02393248 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.